期刊名称：UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. This new journal combines the original research from Urologic Oncology with the comprehensive single topic overviews from Seminars in Urologic Oncology. The combined publication delivers timely clinical research and up-to-date comprehensive reviews of critical scientific relevance. Each issue comprises original articles and reviews including an in depth Seminar examining a specific clinical dilemma. All articles are of significant interest to all clinicians involved in the practice of urologic oncology including urologists, oncologist and radiologists.
|
Editorial Office |
|
Urologic Oncology
Department of Urology
Box 1272
Mt. Sinai Medical Center
1 Gustave Levy Place
New York NY 10029-6574
USA
Tel: +1 212-241-8711
Fax: +1 212-876-3276
|
|
Questions About Using or Accessing this Website |
|
North America and Rest of World
Hours: Monday - Friday, 7:30am - 6:00pm, EST
Tel: (800) 654-2452 (Toll Free US & Canada)
Tel: (314) 447-8871 (Outside US & Canada)
E-mail: JournalsOnlineSupport-usa@elsevier.com
|
Questions About Your Print Subscription
Asia and Australia
Customer Service Department
Winsland House I
3 Killiney Road #08-01
Singapore 239519
Tel: +65 6349-0222
Fax: +65 6733-1510
E-mail: JournalsCustomerServiceAPAC@elsevier.com
|
Web Advertising |
|
Luis Portero
Elsevier
360 Park Avenue South
New York, NY 10010-1710
USA
Tel: +1 212-633-3970
Fax: +1 212-633-3820
E-mail: l.portero@elsevier.com
|
|
Commercial Reprints |
|
Anne Rosenthal
Elsevier Inc.
360 Park Avenue South
New York, NY 10010-1710
Tel: +1 212-633-3812
Fax: +1 212-633-3820
E-mail: reprints@elsevier.com
|
Instructions to Authors
|
Manuscripts and other communications should be submitted to UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS online at http://www.ees.elsevier.com/uro , following the instructions to authors delineated on that site.
UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS supports basic and clinical research subjects. Original articles which address any aspect of urologic oncology are invited. Review articles will also be accepted, although authors are invited to inquire about given topics. Suggestions of topics for the Seminars, News and Topics, and Survey Sections are invited. Those interested in participating in these should contact the managing editor at estherschweizer@verizon.net and copied to michael.droller@mountsinai.org.
All articles will be peer reviewed with the understanding that they are original work, are not being considered for publication elsewhere, and have not been previously published. Letters to the editor are encouraged and will be published as space permits.
Original and Review articles are automatically available online as "In Press" after completing the proofing process. This early online release is not a draft version since it is produced after all editorial and author corrections are made. This "In Press" version is removed as soon as the corresponding monthly issue is available online.
Format
1) Manuscripts should be submitted double-spaced. They should have a face sheet upon which are recorded the title of the work, the authors' names with degrees, institutional affiliations, a complete mailing address, phone, fax, and e-mail address for the individual to whom correspondence should be directed.
2) A summary, not to exceed 350 words, should include objectives, methods and materials, results and conclusions. Acknowledgments, tabular material, figure legends, and references should be submitted separately. Authors must submit up to six keywords with the manuscript.
3) All tables should be submitted separately, be numbered with Arabic numerals and have descriptive titles.
4) All figures should be submitted separately and be numbered consecutively with Arabic numerals. Figures should be accompanied by legends, also submitted separately, which should include descriptive titles and, if needed, an explanation of what the figure represents.
5) All illustrations must be submitted online. For line artwork, black-ink drawings must be of professional quality. Radiologic images must be of sufficient quality and clarity to allow ready visualization of the finding(s) being described, with appropriate labelling as indicated. Color illustrations will be printed at the author's expense. Once a manuscript is accepted for publication, the exact charge will be determined by the publisher.
6) Footnotes to the text should be numbered consecutively with superior Arabic numerals.
7) Approval by the Institutional Internal Review Board for animal and/or clinical studies must be stated in the Methods and Materials section. These requirements should be consistent with the rules of the country of origin.
8) References. List all authors when six or fewer; when seven or more, list the first three and add et al. Authors are responsible for completeness and accuracy of all references. Citation in the text is by number in brackets (i.e., [1]), corresponding to the numbered reference list at the end of the article. Periodical abbreviations should follow those given by Index Medicus. References should be styled as follows:
Journal
Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425-38.
Book
Katz DH. Lymphocyte differentiation, recognition and regulation. New York: Academic Press, 1977.
Chapter in a book
Ceppellini R, Curtoni ES, Mattiuz PL, Miggiano V, Scudeller G, Serra A. Genetics of leukocyte antigens: A family study of segregation and linkage. In: Curtoni ES, Mattiuz PL, Tosi RM, editors. Histocompatibility. Copenhagen: Munksgaard, 1967. pp. 189-202.
9) The system used for tumor classification must be referenced with TNM terminology. Acronyms and other abbreviations should be first defined and then remain consistent throughout the manuscript. Generic names should be followed by the correct chemical name when first used; trade names should not be used. Normal values should be given for all laboratory studies that are unique, vary according to the technique used (the technique should also be mentioned) or are important in interpreting results and drawing conclusions.
10) Conflict of interest. A statement concerning any financial relationship or conflict of interest between any of the authors and the subject matter should be submitted and can be downloaded from the submission site and submitted with the manuscript.
Delay in review can be avoided if authors not familiar with the English language acquire the assistance of an expert for review prior to submission.
Revised manuscripts. Revised manuscripts should be returned to the Editorial Office online within 60 days of receiving notice that revision is suggested, along with a detailed letter describing the changes made or arguments for opposing changes suggested by the reviewers. Failure to submit a revised manuscript by the 60-day deadline will result in the manuscript being automatically withdrawn from the resubmission process. Submission of a revised manuscript will then require review as a new manuscript.
Copyright. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information under U.S. Copyright Law.
Proofs and reprints. The corresponding author will receive proofs online, which should be corrected and returned within 48 hours of receipt. Proofs must be carefully checked by the authors, as it is their responsibility to see that all errors are corrected and queries from editors answered. To order reprints use the order form and price list accompanying the proofs.
When the article has been accepted for publication and is in production, author information and manuscript status is available at: http://www.elsevier.com/authors .
Queries or requests for additional information that is not addressed on the journal website should be sent to estherschweizer@verizon.net.
| |
Editorial Board
Editor:
Michael J. Droller, MD
New York, NY, USA
Former Editors:
G. R. Prout, MD, PhD, (Founding Editor, 1995-1999), Annapolis, MD, USA
James E. Montie, MD, (2002-2006), Ann Arbor, MI, USA
Managing Editor:
E. Schweizer, New York, NY, USA
Seminars Section Editors:
M. Schoenberg MD, Baltimore, MD, USA
S. Campbell MD, PhD, Cleveland, OH, USA
Society of Urologic Oncology Proceedings
R. C. Flanigan MD, Chicago, IL, USA
News and Topics Editors:
R. R. Bahnson MD, Columbus, OH, USA
J. Presti MD, Stanford, CA, USA
Translational Urologic Oncology:
K. R. Loughlin MD, Boston, MA, USA
Survey Editors:
K. S. Koeneman MD, Laboratory Research, Minneapolis, MN, USA
B. Konety MD, Clinical Research, San Francisco, CA, USA
Associate Editors:
P. Albertson MD, Farmington, CT, USA
D. Bostwick MD, Richmond, VA, USA
M. K. Gospodarowicz MD, Toronto, Canada
M. Katan PhD, Cleveland, OH, USA
E. A. Klein MD, Cleveland, OH, USA
D. Raghavan MD, PhD, Cleveland, OH, USA
P. F. Schellhammer MD, Norfolk, VA, USA
J. A. Smith, Jr. MD, Nashville, TN, USA
News and Topics Editors:
Cancer Prevention
J. B. Thrasher MD, Kansas City, KS, USA
B. Dalkin MD, Tucson, AZ, USA
Clinical Studies and Protocols
D. E. Crawford MD, Denver, CO, USA
S. P. Lerner MD, Houston, TX, USA
EORTC and International Studies
Z. Kirkali MD, Izmir, Turkey
C. N. Sternberg MD, Rome, Italy
Epidemiology and Carcinogenesis
S. M. Cohen MD, PhD, Omaha, NE, USA
G. Steineck MD, Stockholm, Sweden
Medical Oncology:
P. Kantoff MD, Boston, MA, USA
D. Trump MD, Buffalo, NY, USA
N. J. Vogelzang MD, Las Vegas, NV, USA
Gene Therapy/Immunotherapy
S. J. Hall MD, New York, NY, USA
J. Vieweg MD, Durham, NC, USA
Health Policy and Socioeconomics
C. A. Olsson MD, New York, NY, USA
W. Gee MD, Lexington, KY, USA
Molecular Biology and Genetics
S. B. Malkowicz MD, Philadelphia, PA, USA
R. Vasella PhD, Seattle, WA, USA
New Technologies
A. Belldegrun MD, Los Angeles, CA, USA
J. Landman MD, New York, NY, USA
J. S. Wolf Jr. MD, Ann Arbor, MI, USA
Outcomes Research
J. W. Moul MD, Durham, NC, USA
D. Penson MD, Los Angeles, CA, USA
Surgery
J. Stein MD, Los Angeles, CA, USA
S. J. Savage MD, Charleston, NC, USA
Urologic Pathology
D. J. Grignon MD, Detroit, MI, USA
M. Rubin MD, Boston, MA, USA
Radiation Oncology
A. V. D'Amico MD, PhD, Boston, MA, USA
H. Sandler MD, Ann Arbor, MI, USA
Translational Studies
M. Benson MD, New York, NY, USA
P. H. Lange MD, Seattle, WA, USA
Tumor Markers
H. B. Grossman MD, Houston, TX, USA
L. G. Gomella MD, Philadelphia, PA, USA
Editorial Board:
P. A. Abrahamsson MD, PhD, Malmo, Sweden
G. Bartsch MD, Innsbruck, Austria
L. Boccon-Gibod MD, Paris, France
C. Cordon-Cardo MD, PhD, New York, NY, USA
F. M. J. Debruyne MD, PhD, Nijmegen, The Netherlands
R. de Vere White MD, Sacramento, CA, USA
Y. Fradet MD, Quebec, Canada
R. A. Gardiner MD, Brisbane, Australia
S. L. Goldenberg OBC, MD, Vancouver, BC, Canada
F. Habib PhD, Edinburgh, Scotland
H. Huland MD, Hamburg, Germany
C. Logothetis MD, Houston, TX, USA
K. Marumi MD, Tokyo, Japan
D. M. Peehl PhD, Stanford, CA, USA
K. Pienta MD, Ann Arbor, MI, USA
J. P. Richie MD, Boston, MA, USA
P. J. Russell PhD, Sydney, Australia
P. T. Scardino MD, New York, NY, USA
H. I. Scher MD, New York, NY, USA
W. A. See MD, Milwaukee, WI, USA
A. Stapleton MD, Melbourne, Australia
U. Studer MD, Bern, Switzerland
D. Wood MD, Ann Arbor, MI, USA
D. K. Yoon MD, Seoul, Korea
|
刊名字顺( Alphabetical List of Journals):
返回页首 